A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy

Immunology

Volumn 119, Issue 1, 2006, Pages 74-82

  Price, Patricia ^a,b,d   Keane, Niamh M ^a,b   Lee, Silvia ^a,b   Lim, Andrew F Y ^a,b   McKinnon, Elizabeth J ^c   French, Martyn A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d Medical Research Foundation Building   (Australia)

Author keywords

Antiretroviral therapy; CMV; Cytokines; HIV; T cells

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CD3 ANTIGEN; CD30 ANTIGEN; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 4; INTERLEUKIN 4 DELTA 2; INTERLEUKIN 5; MESSENGER RNA; MITOGENIC AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; LEUKOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION GENE 3; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; AGED; ALTERNATIVE SPLICING; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD3; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-4; INTERLEUKIN-5; MIDDLE AGED; MITOGENS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME;

EID: 33746903917     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02407.x     Document Type: Article

References (43)

1. Ullum H, Cozzi Lepri A, Bendtzen K, Victor J, Gotzche PC, Phillips AN, Skinhoj P, Karlund Pedersen B. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res Hum Retroviruses 1997; 13:1039-46.
2. Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995; 16:76-80.
3. Sieg SF, Mitchem JB, Bazdar DA, Lederman MM. Close link between CD4+ and CD8+ T cell proliferation defects in patients with HIV disease and relationship to extended periods of CD4+ lymphopenia. J Infect Dis 2002; 185:1401-16.
4. Lederman HM, Williams PL, Wu JW et al. AIDS Clinical Trials Group 889 Study Team. Incomplete immune reconstitution after initiation of HAART in HIV-infected patients with severe CD4+ cell depletion. J Infect Dis 2003; 188:1794-803.
5. Keane NM, Price P, Lee S, Almeida CA, Stone SF, James I, French MA. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. HIV Med 2004; 5:407-14.
6. Burgess K, Price P, James IR, Stone SF, Keane NM, Lim AYF, Warmington JR, French MA. Interferon-gamma responses to Candida recover slowly or remain low in immunodeficient HIV patients responding to ART. Clinical Immunol 2006; 26:160-7.
7. Lee S, Almeida CA, French MAH, Price P. Persistent HIV-1 replication does not explain low levels of T-cell interferon-γ mRNA and elevated serum NO2-/NO3- in patients with stable CD4 T-cell responses to HAART. Clin Exp Immunol 2004; 138:110-5.
8. Ma X, Montaner LJ. Pro-inflammatory response and IL-12 expression in HIV-1 infection. J Leukoc Biol 2000; 68:383-90.
9. Lee S, French MAH, Price P. IL-23 and IFN-[gamma] deficiency in immunodeficient HIV patients who achieved a long-term increase in CD4 T-cell counts on highly active antiretroviral therapy. AIDS 2004; 18:1337-40.
10. Ferlazzo G, Pack M, Thomas D et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004; 101:16606-11.
11. Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol 2003; 73:49-56.
12. Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch FM. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 1999; 15:1499-508.
13. Lienhardt C, Azzurri A, Amedei A et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002; 32:1605-13.
14. Fletcher HA, Owiafe P, Jeffries D et al. Vacsel Study Group. Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology 2004; 112:669-73.
15. Oravecz T, Pall M, Roderiquez G et al. Regulation of the receptor specificity and function of the chemokine RANTES by DPPIV (CD26)-mediated cleavage. J Exp Med 1997; 186:1865-72.
16. Proost P, Schutyser E, Menten P et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signalling and lymphocyte chemotaxis, while preserving anti-angiogenic properties. Blood 2001; 98:3554-61.
17. Keane NM, Price P, Lee S, Stone SF, French MA. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001; 126:111-6.
18. Seah GT, Rook GA. High levels of mRNA encoding IL-4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested reverse transcriptase-polymerase chain reaction; correlations with serum IgE levels. Scand J Infect Dis 2001; 33:106-9.
19. de Martino M, Rossi ME, Azzari C, Chiarelli F, Galli L, Vierucci A. Interleukin-6 synthesis and IgE overproduction in children with perinatal human immunodeficiency virus-type 1 infection. Ann Allergy Asthma Immunol 1999; 82:212-6.
20. Rodriguez B, Valdez H, Freimuth W, Butler T, Asaad R, Lederman MM. Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. AIDS 2003; 17:1983-5.
21. Notermans DW, De Jong JJ, Goudsmit J et al. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses 2001; 17:1003-8.
22. Voltersvik P, Albrektsen G, Ulvestad E, Dyrhol-Riise AM, Sorensen B, Asjo B. Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr 2003; 34:358-67.
23. Redgrave BE, Stone SF, French MAH, Krueger R, James I, Price P. The effect of combination antiretroviral therapy on CD5+ B-cells, B-cell activation and hypergammaglobulinemia in HIV-1 patients. HIV Med 2005; 6:307-12.
24. + T cell after highly active antiretroviral therapy. J Clin Immunol 2004; 24:379-88.
25. Onlamoon N, Lerdwana S, Ratanasuwan W, Suwangool S, Puthavathana P, Pattanapanyasat K. Intracellular production of type 1 and type 11 cytokines during HIV-1 progression in Thai patients. Asian Pac J Allergy Immunol 2003; 21:43-8.
26. Lalani T, Simmons RK, Ahmed AR. Biology of IL-5 in health and disease. Ann Allergy Asthma Immunol 1999; 82:317-32.
27. Moon BG, Takaki S, Nishizumi H, Yamamoto T, Takatsu K. Abrogation of autoimmune disease in Lyn-deficient mice by the deletion of IL-5 receptor alpha chain gene. Cell Immunol 2004; 228:110-8.
28. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005; 174:1037-45.
29. Dheda K, Chang JS, Breen RA et al. In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 172:501-8.
30. Villacres MC, Literat O, Du Degiacomo MW, La Rosa C, Diamond DJ, Kovacs A. Reduced type 1 and type 2 cytokines in antiviral memory T helper function among women coinfected with HIV and HCV. J Clin Immunol 2005; 25:134-41.
31. Seah GT, Gao PS, Hopkin JM, Rook GA. Interleukin-4 and its alternatively spliced variant (IL-4delta2) in patients with atopic asthma. Am J Respir Crit Care Med 2001; 164:1016-8.
32. Arinobu Y, Atamas SP, Otsuka T et al. Antagonistic effects of an alternative splice variant of human IL-4, IL-4delta2, on IL-4 activities in human monocytes and B cells. Cell Immunol 1999; 191:161-7.
33. Price P, Murray R, Johns M, French MAH. Circulating levels of soluble CD30 and DTH responsiveness are inversely related in HIV-infected patients. AIDS 1999; 13:308-9.
34. Katoh N, Hirano S, Suehiro M, Ikenaga K, Yamashita T, Sugawara N, Yasuno H. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol 2000; 121:187-92.
35. Birmann BM, Mueller N, Okayama A et al. Serologic assessment of type 1 and type 2 immunity in healthy Japanese adults. Cancer Epidemiol Biomarkers Prev 2004; 13:1385-91.
36. Biswas P, Mantelli B, Delfanti F, Ferrarini M, Poli G, Lazzarin A. CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and in gamma delta T lymphocytes. Eur J Immunol 2003; 33:3136-45.
37. Blazar BR, Levy RB, Mak TW et al. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol 2004; 173:2933-41.
38. Hargreaves PG, Al-Shamkhani A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol 2002; 32:163-73.
39. Triebel F, Hacene K, Pichon MF. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 2006; 235:147-53.
40. Carlo ED, Cappello P, Sorrentino C et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 antitumour immune pathway. J Pathol 2005; 205:82-91.
41. Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005; 174:688-95.
42. Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunol 2005; 115:170-8.
43. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5:853-65.